About: Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature
Creator	Matthews, David De Silva, Nipun Dissanayake, Harsha Gamage, Kavinga Katulanda, Prasad Piyumi, & Ranathunga, Ishara Ratnasamy, Vithiya Somasundaram, Noel Sumanatilleke, Manilka Wijewickrama, S Yogendranathan, Nilukshana
Source	Medline; PMC
abstract	The coronavirus disease 2019 (COVID-19) pandemic has emerged as one of the greatest challenges faced by humankind in the recent past. People with diabetes and related comorbidities are at increased risk of its complications and of COVID-19-related death. Older age, multi-morbidity, hyperglycaemia, cardiac injury and severe inflammatory response are predictors of poor outcome. The complex interplay between COVID-19, diabetes and the effects of related therapies is being explored. Most patients experience a mild illness with COVID-19, while people with diabetes are at increased risk of severe disease. Optimising glycaemic control and adopting measures to prevent disease spread are critical aspects. The management of mild disease is supportive, while very many immunomodulatory and antiviral therapies are being investigated for the treatment of severe disease. Several of these agents have specific considerations for use in people with diabetes. Since mass population lockdowns are considered a key step in controlling disease spread, it follows that, in addition to the direct vulnerability to severe COVID-19, people with diabetes can be affected by limited access to healthcare, insulin, other medications and blood glucose monitoring equipment. Measures to prevent disease spread at the individual and community level are the key to mitigating the rapidly escalating pandemic, while agents for chemoprophylaxis and vaccines are being explored. People with diabetes should be recognised as a vulnerable group for complicated disease and are at risk during times of disturbed social systems. Strategies are needed to safeguard the health of patients with diabetes during the pandemic. This review summarises the current knowledge and perceived challenges for prevention and management of COVID-19 in people with diabetes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00125-020-05164-x) contains peer-reviewed but unedited supplementary material including a slideset of the figures for download, which is available to authorised users.
has issue date	2020-05-14(xsd:dateTime)
bibo:doi	10.1007/s00125-020-05164-x
bibo:pmid	32405783
has license	cc-by
sha1sum (hex)	e08aa3b5823d539c7074b873130dcca2775f5a67
schema:url	https://doi.org/10.1007/s00125-020-05164-x
resource representing a document's title	Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature
has PubMed Central identifier	PMC7220850
has PubMed identifier	32405783
schema:publication	Diabetologia
resource representing a document's body	covid:e08aa3b5823d539c7074b873130dcca2775f5a67#body_text
is schema:about of	named entity 'prevention' named entity 'management' named entity 'mass' named entity 'diabetes' named entity 'disease' named entity 'disease' named entity 'disease' named entity 'management' named entity 'FACED' named entity 'CRITICAL' named entity 'PAST' named entity 'COMORBIDITIES' named entity 'POOR OUTCOME' named entity 'ITS' named entity 'REVIEW' named entity 'Older' named entity 'pandemic' named entity 'severe' named entity 'risk' named entity 'current' named entity 'measures' named entity 'complications' named entity 'The' named entity 'disease' named entity 'aspects' named entity 'COVID-19' named entity 'agents' named entity 'insulin' named entity 'cardiac' named entity 'diabetes' named entity 'faced' named entity 'people with diabetes' named entity 'insulin' named entity 'people with diabetes' named entity 'people with diabetes' named entity 'Older age' named entity 'people with diabetes' named entity 'People with diabetes' named entity 'COVID' named entity 'antiviral therapies' named entity 'prevent disease' named entity 'COVID' named entity 'COVID-19' named entity 'severe' named entity 'key' named entity 'diabetes' named entity 'clinical outcomes' named entity 'virus' named entity 'China' named entity 'cytokine storm' named entity 'angiotensin' named entity 'downregulate' named entity 'People with diabetes' named entity 'COVID' named entity 'myocardial injury' named entity 'serum ferritin' named entity 'diabetes' named entity 'insulin' named entity 'ACEI' named entity 'hydration' named entity 'heart failure' named entity 'comorbidities' named entity 'CRP' named entity 'consumptive coagulopathy' named entity 'Hydroxychloroquine' named entity 'mucous membranes' named entity 'diabetes' named entity 'TNF-α' named entity 'ACEI' named entity 'Medical therapy'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software